Regional decoupling of n-acetyl-aspartate and glutamate in schizophrenia

Neuropsychopharmacology

Volumn 37, Issue 12, 2012, Pages 2635-2642

  Kraguljac, Nina V ^a   Reid, Meredith A ^a,b   White, David M ^a   Den Hollander, Jan ^c   Lahti, Adrienne C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b and Radiation Oncology   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

anterior cingulate cortex; glutamate (Glx); hippocampus; N acetylaspartate (NAA); proton magnetic resonance spectroscopy (1H MRS); schizophrenia

Indexed keywords

CREATININE; GLUTAMIC ACID; MIRTAZAPINE; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; ANTERIOR CINGULATE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; METABOLITE; NEUROIMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ASPARTIC ACID; BRAIN CHEMISTRY; CEREBRAL CORTEX; FEMALE; GLUTAMIC ACID; HIPPOCAMPUS; HOMEOSTASIS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84867580019     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.126     Document Type: Article

References (53)

1. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y et al (2005). Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58: 85-96.
2. Baker EH, Basso G, Barker PB, Smith MA, Bonekamp D, Horská A (2008). Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J Magn Reson Imaging 27: 489-499.
3. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996). Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7: 1397-1400.
4. Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE (2008). Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 104: 108-120.
5. Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888-1902.
6. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF et al (2001). The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.
7. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH (2005). Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr Res 75: 27-34.
8. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C et al (2010). 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry 15: 629-636.
9. Clark JF, Doepke A, Filosa JA, Wardle RL, Lu A, Meeker TJ et al (2006). N-acetylaspartate as a reservor for glutamate. Med Hypotheses 67: 506-512.
10. Clay HB, Sillivan S, Konradi C (2011). Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int J Dev Neurosci 29: 311-324.
11. Dervaux A, Laqueille X (2008). [Smoking and schizophrenia: epidemiological and clinical features]. L'Encéphale 34: 299-305.
12. Durazzo TC, Gazdzinski S, Banys P, Meyerhoff DJ (2004). Cigarette smoking exacerbates chronic alcohol-induced brain damage: a preliminary metabolite imaging study. Alcohol Clin Exp Res 28: 1849-1860.
13. Flemenbaum A, Zimmermann RL (1973). Inter-and intra-rater reliability of the Brief Psychiatric Rating Scale. Psychol Rep 32: 783-792.
14. Gallinat J, Lang UE, Jacobsen LK, Bajbouj M, Kalus P, von Haebler D et al (2007). Abnormal hippocampal neurochemistry in smokers: evidence from proton magnetic resonance spectroscopy at 3 T. J Clin Pychopharmacol 27: 80-84.
15. Gallinat J, Schubert F (2007). Regional cerebral glutamate concentrations and chronic tobacco consumption. Pharmacopsychiatry 40: 64-67.
16. Garcia M, Huppertz HJ, Ziyeh S, Buechert M, Schumacher M, Mader I (2009). Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS. Epilepsia 50: 486-492.
17. Healy DJ, Meador-Woodruff JH (2000). Ionotropic glutamate receptor modulation preferentially affects NMDA receptor expression in rat hippocampus. Synapse 38: 294-304.
18. Holm S (1979). A simple sequentially rejective multiple test procedure. Scan J Statist 6: 65-70.
19. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al (2012). Elevated prefrontal cortex Y-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69: 449-459.
20. Keltner JR, Wald LL, Christensen JD, Maas LC, Moore CM, Cohen BM et al (1996). A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses. Magn Reson Med 36: 458-461.
21. Kondo DG, Hellem TL, Sung YH, Kim N, Jeong EK, Delmastro KK et al (2011). Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat 2011: 650450.
22. Kraguljac NV, Reid MA, White D, Jones R, den Hollander J, Lowman D et al (2012). Neurometabolites in schizophrenia and bipolar disorderFa systematic review and metaanalysis. Psychiatry Res; e-pub ahead of print. doi:10.1016/j.psychresns. 2012.02.003.
23. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
24. López-Gil X, Babot Z, Amargós-Bosch M, Sunol C, Artigas F, Adell A (2007). Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 32: 2087-2097.
25. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO et al (2010). Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 15: 308-318.
26. Magistretti PJ, Pellerin L (1996). Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann N Y Acad Sci 777: 380-387.
27. Marenco S, Steele SU, Egan MF, Goldberg TE, Straub RE, Sharrief AZ (2006). Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. Am J Psychiatry 163: 740-742.
28. Marsman A, van den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE (2011). Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophrenia Bulletin; e-pub ahead of print 11 July 2011. doi:10.1093/ schbul/sbr069.
29. McLoughlin G, Ma D, Tsamg TM, Jones D, Cilia J, Hill M et al (2009). Analysing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res 8: 1943-1952.
30. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA (2007). N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131.
31. Moreno A, Ross BD, Blüml S (2001). Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion. J Neurochem 77: 347-350.
32. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al (1994). Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51: 849-859.
33. Olbrich HM, Valerius G, Rüsch N, Buchert M, Thiel T, Hennig J et al (2008). Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry 9: 59-63.
34. Pouwels PJ, Frahm J (1997). Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS. NMR Biomed 10: 73-78.
35. Pouwels PJ, Frahm J (1998). Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med 39: 53-60.
36. Randolph C, Tierney MC, Mohr E, Chase TN (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20: 310-319.
37. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS et al (2010). Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68: 625-633.
38. Rosenfeld M, Brenner-Lavie H, Ari SGB, Kavushansky A, Ben-Shachar D (2011). Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol Psychiatry 69: 980-988.
39. Schubert F, Galliant J, Seifert F, Rinneberg H (2004). Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 21: 1762-1771.
40. Shibuya-Tayoshi S, Tayoshi S, Sumitani S, Ueno S, Harada M, Ohmori T (2008). Lithium effects on brain glutamatergic and GABAergic systems of healthy volunteers as measured by proton magnetic resonance spectroscopy. Prog Neuro-psychopharmacol Biol Psychiatry 32: 249-256.
41. Steen RG, Hamer RM, Lieberman JA (2005). Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30: 1949-1962.
42. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH (2008). Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 103: 71-82.
43. Szulc A, Galinska B, Tarasow E, Dzienis W, Kubas B, Konarzewska B et al (2005). The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS). Pharmacopsychiatry 38: 214-219.
44. Tamminga CA, Stan AD, Wagner AD (2010). The hippocampal formation in schizophrenia. Am J Psychiatry 167: 1178-1193.
45. Théberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RWJ, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160: 2231-2233.
46. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
47. van Elst LT, Valerius G, Büchert M, Thiel T, Rüsch N, Bubl E et al (2005). Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 58: 724-730.
48. Vanhamme L, van den Boogaart A, Van Huffel S (1997). Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129: 35-43.
49. Waddell KW, Zanjanipour P, Pradhan S, Xu L, Welch EB, Joers JM et al (2011). Anterior cingulate and cerebellar GABA and Glu correlations measured by 1H J-difference spectroscopy. Magn Reson Imaging 29: 19-24.
50. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM et al (2008). Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320: 539-543.
51. Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U et al (2009). The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch Gen Psychiatry 66: 478-486.
52. Weber OM, Trabesinger AH, Duc CO, Meier D, Boesiger P (1997). Detection of hidden metabolites by localized proton magnetic resonance spectroscopy in vivo. Technol Healthcare 5: 471-491.
53. Wood SJ, Yücel M, Wellard RM, Harrison BJ, Clarke K, Fornito A et al (2007). Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res 94: 328-331.